Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acyclovir for Suppression of HSV and HIV Shedding in Coinfected Persons
NCT00209313Phase 3Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Mar 2005
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in herpes simplex virus type 2 infection comparing Acyclovir First with Placebo First (2 arms). Primary endpoint: HSV and HIV viral shedding at 18 weeks. Started Mar 2005; status: completed.
02
Drugs
aciclovir
03
Conditions
herpes simplex virus type 2 infection
Beyond the preview
Go deeper on NCT00209313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00209313.